Anti-fibrotic drug shows promise in breast cancer

[News]

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of HER2-negative cancers varies among patients, so one goal is to be able to classify tumors in more detail and thus determine the best treatment for each case.

More... (https://www.news-medical.net/news/20240920/Anti-fibrotic-drug-shows-promise-in-breast-cancer.aspx)